{"slug":"canada","tag":"canada","variants":["canada"],"description":"No description yet","count":5,"kinds":{"person":5},"related":[{"slug":"adc","tag":"adc","shared":1},{"slug":"breast","tag":"breast","shared":1},{"slug":"hodgkin","tag":"hodgkin","shared":1},{"slug":"lymphoma","tag":"lymphoma","shared":1},{"slug":"neuroendocrine","tag":"neuroendocrine","shared":1},{"slug":"outcomes","tag":"outcomes","shared":1},{"slug":"prostate","tag":"prostate","shared":1},{"slug":"radioligand","tag":"radioligand","shared":1},{"slug":"radiotherapy","tag":"radiotherapy","shared":1},{"slug":"trialist","tag":"trialist","shared":1}],"records":[{"id":"kim-chi","kind":"person","name":"Kim N. Chi","route":"/people/kim-chi/","tldr":"Led TITAN and MAGNITUDE, bringing apalutamide to hormone-sensitive disease and niraparib to HRR-mutant prostate cancer."},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","tldr":"Led NETTER-2, which moved lutetium dotatate into first-line treatment of higher-grade neuroendocrine tumours."},{"id":"laurie-sehn","kind":"person","name":"Laurie H. Sehn","route":"/people/laurie-sehn/","tldr":"Lymphoma specialist who wrote the definitive DLBCL review and helped establish polatuzumab and other new agents."},{"id":"joseph-connors","kind":"person","name":"Joseph M. Connors","route":"/people/joseph-connors/","tldr":"Led ECHELON-1, which replaced bleomycin with brentuximab vedotin in first-line advanced Hodgkin lymphoma."},{"id":"timothy-whelan","kind":"person","name":"Timothy J. Whelan","route":"/people/timothy-whelan/","tldr":"Led the Canadian trials that established three-week breast radiotherapy and defined when nodal radiotherapy helps."}]}